Neal Dave, PharmD, the executive director of pharmacy at Texas Oncology, discusses the potential for biosimilar utilization to grow and the reasons why his practice favors them over reference products.
Neal Dave, PharmD, the executive director of pharmacy at Texas Oncology, discusses the potential for biosimilar utilization to grow and the reasons why his practice favors them over reference products.
Transcript:
Would you say that there’s still plenty of room for growth of biosimilars in oncology, given current regimens and actual use relative to the need?
There's room. So, I can speak for where I work and I know we've gone all in on the biosimilars as they came out, specifically last year, and we're using close to 90%, and over 90% in some of the biosimilars that are out there. So, there's still a little bit of room even for us to grow. A lot of times what happens is a research protocol, like in our case, where it's mandated to use the brand [reference product], or it's maybe a payer that's doing that. But if we have the choice, in our case, we're using biosimilar because it does decrease the cost of care and it's essentially the same product. It's not entirely a generic, but you have the same effectiveness. And so, the FDA has approved it that way and so we've used them that way. Now, I don't know if that's the case across the whole health care spectrum, in every clinic and every hospital system. So, there is room, I think, still for growth for sure to decrease the overall cost of care.
New Insights Into Meth-Associated PAH Care Gaps: Anjali Vaidya, MD, on Closing the Divide
June 4th 2025Research from Anjali Vaidya, MD, FACC, FASE, FACP, Temple University Hospital, reveals critical care gaps for patients with methamphetamine-associated pulmonary arterial hypertension (PAH), emphasizing the need for early diagnosis and integrated support.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Tailored Dosing for MM Matters More Than Drug Count: Ajai Chari, MD
April 25th 2025When it comes to treating multiple myeloma (MM), Ajai Chari, MD, argued that more is not always better. More intense treatment regimens, or those with more drugs, don't necessarily guarantee better outcomes.
Read More